Data Reliability and Coding Completeness of Cancer Registry Information Using Reabstracting Method in the National Cancer Institute: Thailand, 2012 to 2014

Sirirungreung, Anupong; Buasom, Rangsiya; Jiraphongsa, Chuleeporn; Sangrajrang, Suleeporn

doi:10.1200/jgo.17.00147

Cited by 7 publications

(15 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite this slight shortfall, the registry's overall competence performance remains creditable. Similar to the previous studies in Thailand (32) and India (33) which also found high percent of completeness of data above ninety percent. The study in Finland presented a hundred percent complete of the records was higher as compared to the current findings (34).…”

Section: Discussionsupporting

confidence: 90%

Quality of Data in Population-Based Cancer Registry and its Implications for Cancer Control: A Cross-Sectional Study in Northern Tanzania

Alloyce,

Amour,

Mushy

et al. 2024

Preprint

View full text Add to dashboard Cite

Background: Cancer remains a significant global health challenge, especially in low-resource settings where limited data obstructs effective control measures. Reliable cancer registries are essential tools for collecting, managing, and analyzing cancer-related data. In Tanzania, as in many other sub-Saharan African countries, the need for accurate and timely cancer data is critical for informed decision-making. This study assesses the data quality of a population-based cancer registry in Tanzania to improve cancer control efforts. Methodology: This study adopted a descriptive cross-sectional study design to analyze 9617 records of cancer patients in population-based cancer registry database (Canreg5) from 2018 to 2022. Data analysis is done using Stata 17.0 and IARC validity check software. The percentage of complete, valid, and timely records was computed and compared with the required target. Comparability analysis compared age-standardized rates (ASR) and percentages of morphologically verified (MV%) against the standards in sub-Saharan Africa. Results: In the defined period from 2018 to 2022, a total of 9,617 records were included in the final analysis. The study found high data quality indicators: completeness at 94% for mandatory variables, validity at 76%, timeliness at 93%, and a high comparability with cancer data in sub-Saharan Africa at 60%. However, variations were noticed in age-standardized rates (ASR) and morphologically verified cases (MV). For comparability findings, mouth and pharynx cancer had lower age-standardized rates (ASR) for males (5.7) and females (3.4) but high morphological verification rates. Esophageal cancer had significantly higher ASR for males (22.0) and females (6.1), with moderate morphological verification rates. Stomach cancer had lower ASR but higher verification rates. Colon, rectum, and anus cancer had comparable ASR and higher verification rates. Conclusion: The data quality in the population-based cancer registry at the study site was optimal, with a high proportion of completeness, timeliness, and comparability, but with suboptimal validity of data, particularly for date format, and unlike combinations that highlight continuous monitoring and quality checks. While data quality is vital, challenges like missing and invalid records persist, necessitating reinforced protocols and validation measures.

show abstract

Section: Discussionsupporting

confidence: 90%

Quality of Data in Population-Based Cancer Registry and its Implications for Cancer Control: A Cross-Sectional Study in Northern Tanzania

Alloyce,

Amour,

Mushy

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…We though believe that our data give a realistic estimate of the order of magnitude of the issue. d. Furthermore, these results may have been influenced by documentation disparities, which have been demonstrated to occur in a significant number of patients in similar studies [9,[42][43][44][45][46][47][48][49]. e. We have no data to estimate to which extent complications emerging in the course of treatment might have influenced the results of this study, though e.g.…”

Section: Discussionmentioning

confidence: 84%

Prescription Rates for Antiplatelet Therapy (APT) in Coronary Artery Disease (CAD) – What Benchmark are We Aiming at in Continuing Medical Education (CME)?

Hagen

Griebenow

2020

Journal of European CME

View full text Add to dashboard Cite

Physicians always aim to improve their patients' health. CME should be designed not only to provide knowledge transfer, but also to influence clinical decision-making and to close performance gaps. In aretrospective study we analysed prescription rates for APT in 254,932 CAD patients (male: 64.4%), treated in atotal of 3,405 practices in 2019 in aDMP in the region of North Rhine, Germany. Analyses were run for the whole study population stratified by sex as well as for subgroups of patients suffering from myocardial infarction/acute coronary syndrome, or who have been treated with percutaneous coronary intervention or bypass surgery. Patients mean age was 72.7 ± 11.2 years (mean ± 1SD), mean duration of DMP participation was 7.2 ± 4.7 years, and mean cumulative number of DMP visits was 27 ± 17. APT prescription rates were 85.0% in male and 78.8% in female CAD patients. In subgroups of male CAD patients APT prescription rates were between 89.7% and 92.8%, in the same subgroups of female CAD patients the corresponding rates were between 87.8% and 92.0%. Rates for amissing APT prescription per practice were between .0044% and .0062% for male and female CAD patients, respectively. Rates for amissing APT prescription per practice and DMP visit were .0002% for both sexes. These results suggest that a DMP can achieve high attainment rates for APT in CAD. To further improve attainment rates, consideration of absolute numbers of eligible patients per practice or physician is probably more appropriate than expression of performance as percentage values. This is especially true if attainment rates show substantial variations between subgroups, if subgroups show substantial variation in size, if attainment rates are already in the magnitude of 80% or higher, and if there are disparities in the evidence base underlying treatment recommendations related to subgroups.

show abstract

“…We chose to compare incident malignancy rates between our KTRs and the Thai general population between 2013 and 2015. We only selected the 2013–2015 period because the place of residence to be matched with that of our KTRs in the registry had been validated by cross-checking with the Ministry of Interior’s National Civil Registration records [ 9 ]. Additionally, data after 2016 were not available when we conducted the analysis.…”

Section: Methodsmentioning

confidence: 99%

Incidence of De Novo Post-Transplant Malignancies in Thai Adult Kidney Transplant Recipients: A Single-Center, Population-Controlled, Retrospective Cohort Study at the Highest Volume Kidney Transplant Center in Thailand

Srisuwarn,

Sutharattanapong,

Disthabanchong

et al. 2024

Transpl Int

View full text Add to dashboard Cite

Kidney transplant recipients (KTRs) are at increased risk of developing de novo post-transplant malignancies (PTMs), with regional differences in types with excess risk compared to the general population. A single-center, population-controlled, retrospective cohort study was conducted at a tertiary care center in Thailand among all adults who underwent their first kidney transplant from 1986 to 2018. Standardized incidence ratios (SIRs) of malignancy by age, sex, and place of residence were obtained using data from the National Cancer Registry of Thailand as population control. There were 2,024 KTRs [mean age, 42.4 years (SD 11.4); female patients, 38.6%] during 16,495 person-years at risk. Of these, 125 patients (6.2%) developed 133 de novo PTMs. The SIR for all PTMs was 3.85 (95% CI 3.22, 4.56), and for pooled solid and hematologic PTMs, it was 3.32 (95% CI 2.73, 3.99). Urothelial malignancies had the largest excess risk, especially in women [female SIR 114.7 (95% CI 66.8, 183.6); male SIR 17.5 (95% CI 8.72, 31.2)]. The next two most common cancers were non-Hodgkin’s lymphoma and skin cancer [SIR 20.3 (95% CI 13.6, 29.1) and 24.7 (95% CI 15.3-37.8), respectively]. Future studies are needed to identify the risk factors and assess the need for systematic screening among PTMs with excess risk in KTRs.

show abstract

Data Reliability and Coding Completeness of Cancer Registry Information Using Reabstracting Method in the National Cancer Institute: Thailand, 2012 to 2014

Cited by 7 publications

References 17 publications

Quality of Data in Population-Based Cancer Registry and its Implications for Cancer Control: A Cross-Sectional Study in Northern Tanzania

Quality of Data in Population-Based Cancer Registry and its Implications for Cancer Control: A Cross-Sectional Study in Northern Tanzania

Prescription Rates for Antiplatelet Therapy (APT) in Coronary Artery Disease (CAD) – What Benchmark are We Aiming at in Continuing Medical Education (CME)?

Incidence of De Novo Post-Transplant Malignancies in Thai Adult Kidney Transplant Recipients: A Single-Center, Population-Controlled, Retrospective Cohort Study at the Highest Volume Kidney Transplant Center in Thailand

Contact Info

Product

Resources

About